MyD88抗体;MyD88 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD49B mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HT1080 cells using CD49B mouse mAb (green) and negative control (red).    

  
  

MyD88 (Myeloid Differentiation Primary Response 88) is a critical adaptor protein in innate immune signaling, primarily involved in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways. It mediates downstream signaling by recruiting kinases like IRAKs, leading to NF-κB activation and pro-inflammatory cytokine production. MyD88 antibodies are essential tools for studying immune responses, inflammation, and related diseases. Researchers use these antibodies to detect MyD88 expression, localization, and activation in various cells and tissues through techniques like Western blot, immunohistochemistry, and flow cytometry.

MyD88 dysregulation is linked to cancers (e.g., lymphomas), autoimmune disorders, and chronic infections. Notably, somatic MyD88 mutations (e.g., L265P) are biomarkers in lymphoproliferative diseases, making MyD88 antibodies vital for diagnostic assays. Additionally, they aid in exploring therapeutic strategies targeting MyD88-dependent pathways, such as TLR inhibitor development. Available as monoclonal or polyclonal forms, these antibodies vary in specificity across species (human, mouse, rat), requiring validation for experimental accuracy. Overall, MyD88 antibodies bridge basic research and clinical applications, enhancing understanding of immune pathogenesis and therapeutic innovation.